The Parkinson's Institute and El Camino Hospital join Parkinson's Progression Markers Initiative (PPMI) as offical study site
$40-million, five-year observational clinical study, sponsored by Michael J. Fox Foundation, will seek biomarkers of Parkinson’s disease
 
Published Tuesday, September 28, 2010 4:00 am

SUNNYVALE, Calif., September 28, 2010 — The Parkinson’s Institute, in conjunction with El Camino Hospital announced that it is one of 18 official study sites for the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson’s disease progression. Enrollment of 20 people with Parkinson’s disease and 10 controls at The Parkinson’s Institute will begin this fall, and continue for approximately two years.

“At the Parkinson’s Institute we have been working for over 23 years to end this disease, but have been hindered by the lack of biological markers for disease progression and diagnosis – by solving this problem, this new initiative could greatly speed up testing of new drugs in clinical trials,” notes J. William Langston, MD, Founder and Executive Director of the Institute.  

“PPMI holds potential not only to accelerate the development of breakthrough Parkinson’s treatments for the future, but also to improve diagnosis and treatment of today’s generation of PD patients,” said Caroline Tanner, MD, PhD, Site Principal Investigator.
PPMI participants at the Parkinson’s Institute will undergo the neuroimaging component of the study at El Camino Hospital.

Ramesh Gopi, MD, El Camino Hospital's Vice Chief of Radiology and Nuclear Medicine Investigator for the PPMI study at the Parkinson’s Institute, agreed. “It is deeply meaningful to have been selected as a PPMI site,” he said. “This is a significant step toward our objective of becoming a destination for neuroimaging of movement disorders.”

"Parkinson's is a devastating disease, and our goal is to expand our knowledge of it – and of how to beat it – through advanced imaging and research,” said Imtiaz Qureshi, MD, Medical Director of El Camino's Radiology Department. “With over $20 million invested in the latest imaging equipment, El Camino Hospital has some of the best imaging technology available, making us perfectly suited to partner with The Parkinson’s Institute on this groundbreaking clinical study."

Said Michael J. Fox: “This is an ambitious undertaking, no doubt. But nothing worth having comes easily. Everything we’ve learned up to now, the partnerships we’ve worked to forge, the results of research we’ve funded — it’s all put us in position to launch this effort. We’re ready to roll up our sleeves and, hopefully, get this done.”

Biomarkers: Mission-critical for Parkinson’s Drug Development
A biomarker could be any objectively measurable physical characteristic associated with the presence of disease (diagnostic or risk marker) or any characteristic that changes over time in a way that can be tied to the progression of disease (progression marker).
 “There is no doubt that finding a biomarker is critical to the development of next-generation therapies, and that the lack of this tool is among the most critical issues facing the PD research field,” said Katie Hood, CEO of The Michael J. Fox Foundation. “MJFF has funded biomarker discovery efforts for years. Now we are poised for a concerted, unified effort that will take these discoveries to the next level.”
The lack of a PD biomarker impedes PD diagnosis and treatment, and also critically stalls the development of improved therapies, particularly therapies to slow or stop the progression of PD, something no currently available treatment can do. Clinical trials of new, potentially disease-modifying Parkinson’s treatments are at risk of yielding inconclusive results, because there is no way to measure the effects of those treatments objectively.
# # #

About The Parkinson’s Progression Markers Initiative (PPMI)
PPMI, a groundbreaking study to find biomarkers of Parkinson’s disease, will be carried out over five years at 18 clinical sites in the United States and Europe. The study will enroll 400 de novo Parkinson’s patients (patients who are newly diagnosed and have not yet taken PD medication) and 200 healthy age-matched controls. Participants will undergo tests including motor, neuropsychiatric and cognitive examinations; brain imaging with DatSCAN™ and MRI; and blood, CSF, urine and DNA sampling. For information on enrolling in PPMI, please contact site coordinator Linda Rees at (408) 542 5664, or lrees@thepi.org.

About The Michael J. Fox Foundation
The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson’s disease through an aggressively funded research agenda. MJFF has funded over $175 million in research to date.  

About the Parkinson’s Institute and Clinical Center
Founded in 1988, The Parkinson’s Institute and Clinical Center (PI) is America’s only independent non-profit organization that provides basic and clinical research, clinical trials and a comprehensive movement disorder patient clinic for Parkinson’s disease (PD) and related neurological movement disorders, all under one roof. Our mission is to find the causes, provide first class patient care and discover a cure.  Our unique freestanding organization supports a strong collaboration of translational medicine designed to more directly connect research to patient care – from the "bench to bedside."

About El Camino Hospital
El Camino Hospital is an acute care, 542-bed, not-for-profit and locally-governed organization with campuses in Mountain View and Los Gatos, Calif. In addition to a state-of-the-art emergency department, key medical specialty focuses include cancer care, heart and vascular, neuroscience, genomic medicine, orthopedic and spine and women’s health. El Camino Hospital has delivered the highest level of medical services to the communities of Silicon Valley for more than four decades. The hospital is also recognized as a national leader in the use of health information technology to promote patient safety, including computerized order entry, electronic medical records and wireless communications. El Camino Hospital has been recognized for its clinical excellence with awards such as: Gold Seal of Approval from The Joint Commission for Primary Stroke Center; ANCC Magnet Recognition for Nursing Care and Bay Area Parent Magazine’s Award for Best Hospital or Clinic.
To learn more about El Camino Hospital, the services it provides in Mountain View and Los Gatos, and its commitment to doing “Whatever it Takes” to provide the best and safest patient care, visit our Web site at www.elcaminohospital.org, find us on Facebook at www.facebook.com/elcaminohospital, or follow us on Twitter at twitter.com/elcaminohosp. For a physician referral, visit our Web site or call the El Camino Health Line at 800-216-5556.

 


Send this page to a friend

Show Other Stories

675 Almanor Avenue | Sunnyvale, CA 94085
408.734.2800 main | 408.734.8455 fax (Main) | 408.734.9208 fax (Clinic Secure)